327441
Platinum
powder, 0.5-1.2 μm, ≥99.9% trace metals basis
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
Empirical Formula (Hill Notation):
Pt
CAS Number:
Molecular Weight:
195.08
EC Number:
MDL number:
UNSPSC Code:
12352300
PubChem Substance ID:
Recommended Products
Assay
≥99.9% trace metals basis
form
powder
resistivity
10.6 μΩ-cm, 20°C
particle size
0.5-1.2 μm
bp
3827 °C (lit.)
mp
1772 °C (lit.)
density
21.45 g/cm3 (lit.)
SMILES string
[Pt]
InChI
1S/Pt
InChI key
BASFCYQUMIYNBI-UHFFFAOYSA-N
General description
Average particle size determined by Fisher sub-sieve sizer
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Flam. Sol. 1
Storage Class Code
4.1B - Flammable solid hazardous materials
WGK
nwg
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Personal Protective Equipment
dust mask type N95 (US), Eyeshields, Gloves
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tao Xiong et al.
Journal of biomedical nanotechnology, 9(2), 274-280 (2013-05-01)
Noninvasive molecular fluorescence imaging in vivo which combines Optical imaging with genetic marker technology can real time monitor the development of tumor, through the use of human adenoid cystic carcinoma cell (ACC-M) and lung carcinoma cells SPC-A1 were thansfected by
Yao-Hsuan Tseng et al.
Biochimica et biophysica acta, 1830(6), 3787-3795 (2013-04-02)
Traditional antibacterial photocatalysts are primarily induced by ultraviolet light to elicit antibacterial reactive oxygen species. New generation visible-light responsive photocatalysts were discovered, offering greater opportunity to use photocatalysts as disinfectants in our living environment. Recently, we found that visible-light responsive
Hiroaki Akamatsu et al.
Japanese journal of clinical oncology, 43(6), 664-668 (2013-04-16)
Interstitial lung disease associated with gefitinib is a critical adverse reaction. When geftinib was administered to EGFR-unknown patients, the interstitial lung disease incidence rate was approximately 3-4% in Japan, and usually occurs during the first 4 weeks of treatment. However
Catalysis: The accelerator.
Mark Peplow
Nature, 495(7440), S10-S11 (2013-03-15)
Downregulation of glutathione transferase π sensitizes lymphoma/leukaemia cells to platinum-based chemotherapy.
Jianli Chen et al.
British journal of haematology, 162(1), 135-137 (2013-04-12)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service